EP1140097A2 - Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use - Google Patents
Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and useInfo
- Publication number
- EP1140097A2 EP1140097A2 EP99967471A EP99967471A EP1140097A2 EP 1140097 A2 EP1140097 A2 EP 1140097A2 EP 99967471 A EP99967471 A EP 99967471A EP 99967471 A EP99967471 A EP 99967471A EP 1140097 A2 EP1140097 A2 EP 1140097A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- alcohol
- product
- aqueous solvent
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LXOPCHVYWBGPND-UHFFFAOYSA-N 4-(2-phenylethenyl)benzene-1,2,3-triol Chemical class OC1=C(O)C(O)=CC=C1C=CC1=CC=CC=C1 LXOPCHVYWBGPND-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 236
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 166
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 115
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000000463 material Substances 0.000 claims abstract description 17
- 230000008569 process Effects 0.000 claims description 218
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 189
- 239000000047 product Substances 0.000 claims description 169
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 147
- 238000010828 elution Methods 0.000 claims description 124
- 235000021286 stilbenes Nutrition 0.000 claims description 58
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 57
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 55
- 239000007787 solid Substances 0.000 claims description 51
- 238000011068 loading method Methods 0.000 claims description 47
- 230000005526 G1 to G0 transition Effects 0.000 claims description 37
- 239000012141 concentrate Substances 0.000 claims description 36
- 238000005406 washing Methods 0.000 claims description 20
- 239000002002 slurry Substances 0.000 claims description 19
- 239000003495 polar organic solvent Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- -1 poly(caprolactam) Polymers 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- LXOPCHVYWBGPND-VOTSOKGWSA-N 4-[(e)-2-phenylethenyl]benzene-1,2,3-triol Chemical class OC1=C(O)C(O)=CC=C1\C=C\C1=CC=CC=C1 LXOPCHVYWBGPND-VOTSOKGWSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 4
- 241000205407 Polygonum Species 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical class C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 150000001629 stilbenes Chemical class 0.000 claims description 3
- 229920002302 Nylon 6,6 Polymers 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 238000004587 chromatography analysis Methods 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract 1
- 229940016667 resveratrol Drugs 0.000 description 48
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 29
- 235000021283 resveratrol Nutrition 0.000 description 28
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 27
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000007858 starting material Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- 230000001143 conditioned effect Effects 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 7
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229920006122 polyamide resin Polymers 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 5
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 5
- HSTZMXCBWJGKHG-CENDIDJXSA-N Piceid Natural products OC[C@@H]1O[C@@H](Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2)[C@H](O)[C@H](O)[C@H]1O HSTZMXCBWJGKHG-CENDIDJXSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 5
- HSTZMXCBWJGKHG-OUUBHVDSSA-N piceide Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-OUUBHVDSSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000020095 red wine Nutrition 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101001056976 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) Catalase-peroxidase Proteins 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical class CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- AYRABHFHMLXKBT-UHFFFAOYSA-N 2,6-Dimethyl-anthracen Natural products C1=C(C)C=CC2=CC3=CC(C)=CC=C3C=C21 AYRABHFHMLXKBT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VWVRASTUFJRTHW-UHFFFAOYSA-N 2-[3-(azetidin-3-yloxy)-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(OC2CNC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VWVRASTUFJRTHW-UHFFFAOYSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
- 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 101150062589 PTGS1 gene Proteins 0.000 description 1
- 108010081873 Persil Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- HSTZMXCBWJGKHG-BUFXCDORSA-N cis-piceid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C/C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-BUFXCDORSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940116441 divinylbenzene Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000021097 low calorie intake Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004748 mammary carcinogenesis Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920006216 polyvinyl aromatic Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000018991 trans-resveratrol Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to trihydroxystilbenes and the glycosylated derivatives thereof.
- the present invention also relates to methods for isolation and purification of these products using reverse phase liquid chromatography and a method for converting glycosylated to aglycone product.
- the present invention further relates to treatment of diseases using compounds of the invention.
- Resveratrol, 3,4',5-trihydroxystilbene was first isolated from grape leaves (Inghim, T.L., Phvtochem.. 15 (1979) (1976)). Inghim characterized the stnicture of resveratrol using chemical methods. Resveratrol has following chemical stnicture in which both Ri and R 2 are hydrogen.
- ⁇ -glc is 0- ⁇ -D-glucose
- Trihydroxystilbenes and derivatives thereof derivatives are reported to have medicinal properties including anti-leukcmic and anti-tumor activities.
- plant material containing resveratrol has been used as an herbal medication for treatment of hyperlupemia and liver diseases in China and Japan for many centuries (Kimura, K.M. et al., Shoygakugaku Zasshi. 83, 35-58 (1981)).
- Subsequent experiments with purified trans- resveratrol demonstrate that the many biologically useful functions including modulation of hepatic cholesterol synthesis, inhibition of lypooxygenase actiuty (Kimura. Y et al . Diochem Biophys Acta . 834.
- ED 50 represents effective dosage for 50% inhibition
- This inhibitory activity is relevant to cancer therapy and prevention because COX catalyzes the conversion of arachidonic acid to pro-inflammatory substances such as prostaglandins, which can stimulate tumor cell growth and suppress immune responses (Plescia, O J. et al , Proc Nat Acad Sci USA , 72, (1975))
- Resveratrol 3,4'5-Trihydroxyst ⁇ lbene
- resveratrol effectively possesses many pharmacological activities which can potentially explain the protective effects of red wine at the cardiovascular level (Frankel, E.N. et al., Lancet, 341 454 (1993)).
- resveratrol has proved capable of promoting the formation of nitroxides which have a vasodilatory action and inhibit platelet aggregation induced by collagen or ADP (Fitzpatrick, D. et al., Am. J Physio 265 (Heart Circ. Phvsiol.). 34 774 (1993)).
- Plant materials that are natural sources for resveratrols include Vitis vinifera and Polygonum cuspidatitm (Huzhang).
- the concentration of resveratrol in P. cuspidatitm is much higher than in V vinifera.
- the procedures currently practiced for isolating resveratrols from plant materials are very difficult and low yielding normal phase chromatographic procedures that also use chlorinated solvents which are toxic to humans and can damage the environment.
- T e isolation of resveratrols from natural sources represents a potential reliable source of supply
- the present invention provides an isolation and purification technique which provides high yields and low cost of production of resveratrol and related compounds SUMMARY OF THE INVENTION
- products containing a stilbene fraction, compositions containing these products, and reverse phase liquid chromatography processes for isolating and purifying these products from plant material are identified
- the present invention provides a first product having a solids content of at least about 60% wherein the solids include at least about 10% by weight of a stilbene fraction and a process for making the product that includes the step of contacting a plant material u ith an alcohol and obtaining the product from the alcohol after contacting
- the present invention further provides a third product made up of at least about 20% by weight of a mixture of trihydroxystilbenes and mono- ⁇ -D-glycosylated trihydroxystilbenes and a composition of the third product with an aqueous solvent
- the composition including the third product is made by an MD-l reverse phase liquid chromotography process.
- the present invention provides fourth products made up of at least
- a stilbene fraction including trihydroxystilbenes and mono- ⁇ -D- glycosylated trihydroxystilbenes and compositions of these fourth products with aqueous solvents.
- Fourth products are made using an MD-2 process starting w ith a composition containing the third product in which a polyamide resin is the stationary phase A composition containing the third product is concentrated to form a loading concentrate that is loaded onto an MD-2 column, optionally using a washing elution volume, followed by elution with one or more MD-2 elution volumes of an aqueous solvent, especially a mixture of an alcohol and water to make an MD-2 effluent that is a composition containing a fourth product The effluent is collected in toto or as gradient fractions collected by fractionate collection.
- Fourth products are obtained by removing aqueous solvent from an MD-2 effluent, however collected.
- the present invention also provides fifth products that are made up of at least about 60% of a stilbene fraction.
- a fifth product can be at least about 85% by weight mono- ⁇ - D-glycosylated trihydroxystilbenes or at least about 85% aglycone thereof.
- compositions including fifth products and an aqueous solvent are made by an MD-3 process in which the stationary phase is silica gel based.
- the starting material for an MD-3 process is an effluent, especially a gradient fraction, from an MD-2 process.
- the effluent is concentrated to form a loading concentrate that is eluted through the MD-3 column and can be followed by a washing elution volume.
- the MD-3 column is then eluted with one or more elution volumes of an aqueous solvent.
- Each elution volume can consist of one or more discrete gradient volumes, each made up of a different aqueous solvent, or the composition of each elution volume can vary linearly, exponentially, logarithyrnically', hy ⁇ erbolically, or stepwise during elution of the elution volume.
- the effluent from a first MD-3 process is a composition containing a fifth product.
- the effluent may be collected in toto or fractionate collected as gradient fractions.
- Fifth products are obtained by removing aqueous solvent from effluent or gradient fractions of a first MD-3 process.
- a gradient fraction of a first MD-3 process is the starting material for a cold crystallization process to make a fifth product that contains at least about 85% by weight mono- ⁇ -D-glycosylated trihydroxystilbene.
- the gradient fraction of a first MD-3 process is concentrated to a solids content of at least about 20g/L and then diluted with water.
- the resulting mixture is cooled to less than about 0°C to fo ⁇ n a slurry from which such fifth product can be isolated, washed, and then dried.
- the present invention provides a second MD-3 process for making compositions containing sixth products that are at least about 70% by weight, trihydroxystilbenes. Sixth products are isolated by removing aqueous solvent from the compositions.
- Starting material for a second MD-3 process is an MD-2 gradient fraction that has been fractionate collected.
- the MD-2 gradient fraction is concentrated to a loading concentrate having a solids content of at least about 7 g/L.
- the MD-3 column is eluted with first and second MD-3 elution volumes that are made up of aqueous solvent.
- Either or both MD-3 elution volumes can be made up of gradient volumes that include different aqueous solvents or the composition of the aqueous solvent of either or both elution volumes may be varied linearly, exponentially, logarithymically, hyperbolically, or stepwise during elution of the respective elution volume.
- Effluents corresponding to the respective elution volumes or gradient volumes can be collected in toto or fractionate collected.
- Sixth products are obtained by removing aqueous solvent from the effluent or gradient fractions of a second MD-3 process, however collected.
- An effluent or gradient fraction of a second MD-3 process is a starting material for making a sixth product that is at least about 85% by weight, 3,4',5-trihydroxy-trans-stilbene in which the effluent or gradient fraction is concentrated to a concentrated composition and twice contacting this concentrated composition with separate extraction volumes of a volatile polar organic solvent (e.g., ethyl acetate), combining the extraction volumes, and removing the volatile polar organic solvent to obtain the 85% product.
- a volatile polar organic solvent e.g., ethyl acetate
- Tlie present invention also provides a third MD-3 process for making a composition containing a seventh product that includes at least 50% by weight of 3,4', 5- trihydroxy-c/ ' -'-stilbene.
- Starting material for a third MD-3 process is a fractionate collected gradient fraction of a second MD-2 process.
- the fractionate collected gradient fraction of a second MD-2 process is concentrated to a solids content of at least about 7 g/L to form a loading concentrate that is eluted through an MD-3 column.
- the third MD-3 process further includes the steps of eluting the MD-3 column with first, second, and third elution volumes that are made up of aqueous solvent.
- Each of the elution volumes can be made up of two or more gradient volumes in which the aqueous solvent has the same or a different composition.
- the elution volumes or gradient volumes result in MD-3 effluents of a third MD-3 process.
- the elution volumes or gradient volumes are collected to toto or fractionate collected.
- the effluents of the third MD-3 elution volume of a third MD-3 process, or gradient fractions thereof are compositions containing the seventh product of the present invention.
- the seventh products of the present invention are obtained by removing aqueous solvent from the effluent resulting from the third MD-3 elution volume of a third MD-3 process, or gradient fractions thereof.
- a process for converting a mono- ⁇ -D-glycosylated trihydroxystilbene to the corresponding aglycone includes the steps of providing a solution or suspension of a glycosolated trihydroxystilbene, contacting the solution or suspension with HC1 at a total concentration between 0.01 and 0.02 g/ml, and refluxing the acidified solution or suspension for about 10 to about 200 minutes.
- the corresponding aglycone is isolated from the reaction mixture by techniques as are known in the art.
- the converting process can be carried out under a blanket of inert gas, for example, nitrogen.
- Alcohol refers to a lower aliphatic alcohol, in particular one selected from the group consisting of methanol, ethanol. the isomeric propanols, the isomeric butanols, the isomeric pentanols, and the isomeric hexanols.
- Aqueous Solvent refers to water or a polar organic solvent that is miscible with water in all proportions from 1 :99 to 99: 1.
- polar organic solvents that are, or can be used, as components of an aqueous solvent, as that term is herein used, includes but is not limited to methanol, ethanol, isopropanol, n-propanol, acetone, and acetonitrile.
- Other suitable polar organic solvents are known to the skilled artesian.
- Column Volume refers to the volume of the space defined by the inner surface of the chromatography column or chamber that surrounds the
- composition is a slurry, suspension, dispersion, or especially a solution of a material, normally solid at room temperature, in an aqueous solvent.
- examples of compositions include but are not limited to loading elutions, loading concentrates, and effluents or gradient fractions from any reverse phase liquid chromatography process of the present invention.
- fractionate collecting denotes that the effluent or gradient effluent or gradient fraction or gradient subfraction is segregated into at least two portions or aliquots.
- An MD-l column is a reverse phase liquid chromatography column of any size in which the stationary phase is a crosslinked copolymer of a vinyl aromatic compound, for example styrcne, cross linked with a polyvinyl aromatic compound, for example divinylbcnzene, wherein the stationary phase has a mean surface area of at least about a 400 nr/g, preferably 800 nr/g, and a porosity of at least about 0.55 ml/ml, preferably at least 0.58 ml/ml.
- the mean diameter of the particles comprising the stationary phase is between about 490 ⁇ and 700 ⁇ .
- the dipole moment of the crosslinked polymer comprising the stationary phase is less than about 0.5.
- MD-2 Column An MD-2 column is a reverse phase liquid chromatography column of any size in which the stationary phase is a polyamide resin.
- polyamide resin is a polymer of a lactam or a copolymer of a diamine and a dicarboxylic acid (or of the salt formed between the diacid and the diamine).
- polyamide resins include poly(caprolactam) and poly(hexamethylene adipamide).
- An alcohol water mixture comprising 10 vol-% methanol is used to condition an MD-2 column.
- An MD-3 column is a reverse phase liquid chromatography column of any size in which the stationary phase is silica gel based reverse phase particles having C 8 to C
- a suitable material is WP Octadecyl reverse phase media available from J.T. Baker, Phillipsburg, New Jersey (Cat. #7248-2).
- An MD-3 column is conditioned with a mixture of methanol and water comprising about 20 vol-% methanol.
- Percent Solid refers to the weight of a nominally solid composition comprising an aqueous solvent that remains after the aqueous solvent is removed. Unless otherwise indicated, the quantity percent solid is expressed as the ratio of the weight of the composition remaining after removal of aqueous solvent divided by the weight of the composition before removal of the aqueous solvent, multiplied by 100.
- a nominally solid composition is a composition that does not flow under its own weight at room temperature.
- compositions are pharmaceutically acceptable organic or inorganic carrier substances that do not react or otherwise interfere with biologically active components of pharmaceuticals or neutriceuticals and which assist in processing the biologically active components, or products containing them, into a form convenient for administering the biologically active components to an animal, including a human.
- Many such pharmaceutically acceptable processing excipients are known in the art. Among these, tricalcium phosphate and maltodextrin are particularly preferred.
- SDA refers to specially denatured alcohol. See U.S. Pharmacopoeia.
- Solids Component The portion of a slurry , suspension, dispersion or solution is an aqueous solvent that remains after the aqueous solvent is removed. Synonymous with solids portion.
- Solids Content quantifies the portion of a solution, slurry, suspension, or dispersion in an aqueous solvent that remains when the aqueous solvent is removed and is expressed in units of grams of solid remaining per liter of solution or slurry and is abbreviated g/L.
- Stilbene fraction refers collectively to the constituents or components of a material especially a solids component, that consists essentially of 1,2- diphenylethenes and substituted 1,2-diphenylethenes, where either or both of the phenyl rings can bear one or more substituents.
- Volume Percent As used herein the term volume percent, abbreviated vol-%, is used to describe the composition of an aqueous solvent. The vol-% of a component represents the ratio of the volume of the component added to a composition to the total of the volumes of all components added to the composition times 100.
- the present invention provides a first product that comprises at least about 60%, preferably at least about 65%, by weight solids which solids comprise at least about 10%, preferably at least about 12%, by weight of a stilbene fraction.
- the first product can be obtained by providing a solid plant material, preferably V. vinifera, more preferably P.
- cuspidatitm which plant material has been cut or ground to pieces having an average volume from about 0.001 mm 3 to about 15 mm 3 , and contacting the plant material with an aqueous solvent, preferably an alcohol-water mixture comprising about 75 volume percent (vol-%) SDA.
- the contacting may be by any suitable means as are known in the art; for example, percolation, vat extraction, counter current extraction, and the like.
- the first product can then be obtained by removing aqueous solvent or a component thereof from the resulting composition.
- aqueous solvent can be removed by any of the means as are known in the art such as evaporation, distillation, and lyophilization, to mention a few.
- the first product can be used to prepare a second product that can be directly administered to an animal, including a human, and which second product has a stilbene fraction amounting to at least about 8% by weight and at least one pharmaceutically acceptable processing excipient.
- the second product is made by slurrying the first product in water and homogenizing the slurry with one or more pharmaceutically acceptable processing excipients.
- a Silverson Model 14 RT-A homogenizer Silverson Corporation, East Longmeadow, MA is suitable for this purpose.
- the homogenized mixture is then dried by spray drying or vacuum drying.
- the first product is also useful as a starting material for preparation of products having a stilbene fraction of at least about 20% by weight or for the preparation of t ⁇ hydrowstilbenes and gly cosylated de ⁇ vatu cs thereof by employing reverse phase liquid chromatography processes
- the column packing (stationary phase, or adsorbent) is non-polar, typicalh having a dipole moment of 3 or less.
- Silica gel that has been treated to provide it with a bonded surface layer that is paraffinic in nature is an example of a stationary phase for reverse phase chromatography.
- Silica gels having permanently bonded C 8 to Cm alky 1 groups are commercially available as a stationary phase
- Reverse phase liquid chromatography columns are eluted with eluents of decreasing polarity which causes the more polar compounds loaded on a column to elute first.
- Reverse phase liquid chromatography stationary phases of organic material are also known.
- Polymers of vinyl aromatic compounds, for example styrene, that are heavily crosslinked with polyviny c aromatic hydrocarbons, for example diviny lbenzene, can be used as stationary phases for reverse phase liquid chromatography
- These organic polymeric stationary phases are made by processes that yield small, extremely rigid, macroreticular particles
- Highly crosslinked acrylic polymers are also useful as stationary phases for reverse phase liquid chromatography.
- Suitable stationary organic phases are commercially available.
- styrenic and acrylic stationary phases are available from the Rohm and Haas Company, Philadelphia, PA, under the trade name Amberhte® Styreneic stationary phases are also available under the trade name Amberchrom® from Tossohass, Montgomeryville, PA
- Polyamide resins e g nylons
- polyester resins e g polyester resins
- phenolic resins are also useful stationary phases for the reverse phase chromatography processes of the present invention
- polar organic solvents are suitable eluents for reverse phase liquid chromatography
- Lower alcohols such as methanol, ethanol, and propanol. as well as nit ⁇ les such as acetonit ⁇ le, are used as organic eluents
- Lower aliphatic ketones such as acetone methyl ethyl kctone, and diethyl ketone, as well as cyclic ethers such as tctrahvdrofiiran, can also be used.
- Dimethyl formamide, dimethyl sulfoxide, and alkyl esters of acetic acid such as ethvl acetate can also be used.
- RPLC processes of the present invention are advantageously carried out using an eluent of variable composition, that is a so-called gradient eluent.
- concentration of gradient eluents are determined by the concentration of polar organic solvent necessary to elute products from the stationary phase and by the requirement that the polar organic solvent be miscible to form a single phase at the required concentration.
- the initial alcohol concentration is 10 volume percent (10 vol-%) or less and is increased as separation and purification proceeds.
- the reverse phase liquid chromatography systems used to practice the present invention may be either preparative or analytical. Preparative columns require larger loading capacity and are typically larger in size.
- Flow rates of the eluent are adjusted according to the column dimensions, the degree of separation desired, the particle size of the stationary phase, and the back pressure in the column.
- the separation is typically carried out at 20°C to 30°C. However, a temperature up to about 45°C can be used.
- the separation may be carried out at high pressure (500-200 psi) or moderate pressures (100-500 psi) or, preferably, at lower pressures (10-100 psi).
- the product to be chromatographically treated is generally provided as a solution or suspension in an aqueous solvent.
- the aqueous solvent is a mixture of an alcohol and water having a volume percent alcohol between about 5 vol-% and about 20 vol-%, as determined by known methods, for example gas chromatography.
- the concentration of product in the solution or suspension to be chromatographically treated is also varied according to the particular embodiment, but is generally between about 0.1 and about 10 g/L.
- the concentration of the product to be treated is such that column loading is between about 1 g L and 12 g/L.
- the reverse phase liquid chromatography column can be conditioned by eluting the column with a conditioning volume of a conditioning liquid, preferably an aqueous solvent.
- the conditioning volume is preferably between about 1 and about 10 column volumes.
- the product to be treated is loaded onto the conditioned stationary phase of the reverse phase chromatography column by means of a solution, a slurry, or, a loading concentrate obtained by evaporating an aqueous solvent, preferably alcohol, from a composition containing the product.
- Loading of the column is accomplished by eluting the solution, slurry, or loading concentrate through the column.
- elution of the solution, slurry, or loading concentrate is followed by elution with a washing elution volume comprising an aqueous solvent having the same composition as the aqueous solvent of the solution, slurry, or loading concentrate used to load the column stationary phase.
- the washing elution volume when one is used, is preferably between about 1 and about 10 column volumes.
- a further embodiment of the present invention provides a third product from an MD-l reverse phase liquid chromatography process having at least about 20% by weight and
- the first product of the present invention is slurried in an aqueous solvent, preferably a mixture comprising between about 3 vol-% and about 7 vol-% alcohol, preferably methanol
- an aqueous solvent preferably a mixture comprising between about 3 vol-% and about 7 vol-% alcohol, preferably methanol
- the first product is loaded onto an MD- l column support by eluting the slurry through the MD-l column and can be followed by a washing elution volume including an aqueous solvent that is preferably a mixture of alcohol and water having between about 5 vol-% and about 20 vol-% alcohol. preferably methanol.
- a composition including the third product can be eluted from the loaded MD-l column stationary phase with a first MD-l elution volume to produce a first MD-l effluent.
- the first MD-l elution volume includes an aqueous solvent, preferably a mixture of alcohol and water having between about 70 vol-% and about 80 vol-%, preferably about 75 vol- %, of an alcohol, preferably a methanol.
- Aqueous solvent can be removed from the first MD-l effluent composition by any suitable means as discussed above, to obtain the third product.
- Yet another embodiment of the present invention provides a fourth product having at least about 30% by weight of a stilbene fraction having a mixture of trihydroxystilbenes and mono- ⁇ -D glycosylated trihydroxystilbenes.
- the fourth product can be obtained by a first MD-2 reverse phase liquid chromatography process.
- Starting material for a first MD-2 process is a first MD-2 loading concentrate having a third product of the present invention in an aqueous solvent, preferably a mixture of alcohol and water comprising not more than about 20 vol-% alcohol, preferably methanol.
- the MD-2 loading concentrate can be made by removing sufficient aqueous solvent from the first MD-l effluent resulting from the first MD-l elution volume so that the solids content of the first MD-2 loading concentrate is at least about 10 g/L, preferably at least about 13 g/L.
- the third product is loaded onto an MD-2 column stationary phase by eluting the first MD-2 loading concentrate through the MD-2 column which can be followed by a washing elution volume.
- the MD-2 column is then eluted with a first MD-2 elution volume to make a first MD-2 effluent
- the first MD-2 elution volume is a mixture of an alcohol, preferably methanol, and water having at least about 60 vol-% and preferably at least about 70 vol-% alcohol, more preferably at least about 75 vol-% alcohol.
- a second MD-2 process which includes the steps of the first MD-2 process
- the MD-2 column is eluted with a first MD-2 elution volume of a second MD-2 process that includes at least a first gradient volume and a second gradient volume, both of which are mixtures of an alcohol, preferably methanol and water, and both of, which can be divided into any number of subgradient volumes.
- the first gradient volume includes between about 20 vol-% and about 40 vol-%, preferably at least about 30 vol- %, of an alcohol, preferably methanol
- the second gradient volume includes between about 70 vol-% to about 80 vol-%, preferably at least about 75 vol-%, of an alcohol, preferably methanol.
- the effluent that results from elution of the first and second gradient volumes can be fractionate collected and segregated into first and second gradient fractions, respectively, of the second MD-2 process that are compositions containing specific embodiments of the fourth product of the present invention.
- either gradient fraction can itself be fractionate collected to obtain gradient sub fractions.
- the first gradient fraction is a composition including a fourth product of the present invention that includes at least about 40% by weight of a stilbene fraction that includes at least about 90% mono- ⁇ -D-glycosylated trihydroxystilbenes and the second gradient fraction is a composition also including a fourth product of the present invention including at least about 30% by weight of a stilbene fraction that has at least about 80% trihydroxystilbenes, preferably 3,4 " ,5- trihydroxystilbenes.
- the respective fourth products can be obtained by removing alcohol-water mixture from the respective gradient fractions.
- Another embodiment of the present invention provides a third MD-2 process for making a composition that includes a stilbene fraction that has at least about 80% and preferably at least about 90% by weight mono- ⁇ -D-glycosylated-3,4',5-trihydroxystilbcne.
- a third product is loaded onto an MD-2 column stationary phase by means of an MD-2 loading concentrate.
- the MD-2 column is eluted with a first MD-2 elution volume of a third MD-2 process.
- the first MD-2 elution volume of a third MD- 2 process is an MD-2 gradient elution volume including a mixture of alcohol and water the composition of which can be varied linearly, exponentially, logarithmically, parabolically, step- wise, or according to any combination of the foregoing.
- the MD-2 effluent is fractionate collected to obtain one or more compositions, each of which contains a fourth product.
- Another embodiment of the present invention provides a fifth product that has at least about 60%, preferably at least about 65%, of a stilbene fraction containing at least about 90% by weight of mono- ⁇ -D-glycosylated-3,4 ⁇ 5-trihydroxy-tr ⁇ m' ⁇ stilbene.
- This embodiment of the fifth product of the present invention can be made in a first MD-3 reverse phase chromatography process.
- Starting material for this first MD-3 reverse phase chromatography process is a loading concentrate made by removing sufficient aqueous solvent from the segregated first gradient fraction of the second MD-2 process or a segregated fraction of the third MD-2 process that includes a stilbene fraction that has at least about 50% of mono- ⁇ -D- glycosylated-3,4'5-trihydroxystilbenes, so that the loading concentrate has a solids content of at least about 3 g/L.
- the first gradient volume of the second MD-2 elution volume is a mixture of alcohol and water
- the loading concentrate preferably has not more than about 5% alcohol.
- the loading concentrate is eluted through an MD-3 column to load the column stationary phase and, in preferred embodiments, is followed by a washing elution that is an aqueous solvent, preferably a mixture of alcohol and water having about 5 vol- % alcohol, preferably methanol, and the volume of the loading elution corresponds to about 0.5 to about 10 column volumes.
- the MD-3 column is then eluted with a first MD-3 elution volume of the first MD-3 process to obtain a first MD-3 effluent of a first MD-3 process that is fractionate collected to obtain a first fraction of a first MD-3 effluent of a first MD-3 process and a second fraction of a first MD-3 effluent of a first MD-3 process.
- the first fraction of the first MD-3 effluent of a first MD-3 process amounts to about 0.5 to about 3, preferably about 1.5, column volumes and the second fraction of the first MD-3 effluent of a first MD-3 process amounts to between about 0.5 and about 3 column volumes, preferably 1 column volume.
- the fifth product that has at least about 60% of a stilbene fraction comprising at least about 90% mono- ⁇ -D-glycosylated-3,4',5-trihydroxy- t/ww-stilbene can be obtained by removing the aqueous solvent from the fractionate collected first MD-3 effluent of a first MD-3 process.
- the present invention provides an evaporative crystallization process for making a fifth product containing at least about 85% and preferably at
- the starting point for the evaporative crystallization process is fractionate collected first MD-3 effluent of a first MD-3 process, preferably a second fraction of a first MD-3 effluent of a first MD-3 process that is fractionate collected after a first fraction of a first MD-3 effluent of a first MD-3 process amounting to 0.5 to about 3 column volumes is collected.
- the second fraction of a first MD-3 effluent of a first MD-3 process is evaporated to between about 0.1 and about 0.2 times its original volume and cooled, preferably to 4°C or below, to form crystals that are a fifth product containing at least about 85% 3,4',5-trihydroxy-/r ⁇ 7/7.y-stilbene-3- ⁇ -mono-D-glucoside.
- the present invention provides a sixth product having at least about 70% and preferably at least about 75% of a stilbene fraction including at least about 70% by weight of 3,4',5-trihydroxy-trfl/w-stilbene.
- the sixth product can be prepared by a second MD-3 process.
- the starting material for the second MD-3 process is the second gradient fraction of the second MD-2 process.
- Aqueous solvent is removed from the second MD-2 gradient fraction of the second MD-2 process to form a loading concentrate having a solids content of at least about 7 g/L.
- the loading concentrate is eluted through an MD-3 column and, in preferred embodiments, can be followed by a washing elution volume including an aqueous solvent, preferably a mixture of alcohol and water including between about 10 vol-% and about 20 vol-% alcohol, preferably methanol.
- the MD-3 column is then eluted with a first MD-3 elution volume of a second MD-3 process having first and second gradient volumes.
- the first gradient volume of the first MD-3 elution volume of the second MD-3 process is preferably an aqueous solvent that is preferably a mixture of alcohol and water having between about 35 vol-% and about 45 vol-%, preferably 40 vol-%, of an alcohol, preferably methanol, and elutes a first MD-3 gradient fraction of a second MD-3 process and is followed by elution with the second MD-3 gradient volume of a first MD-3 elution volume of the second MD-3 process that includes an aqueous solvent, preferably an alcohol-water mixture having between about 50 vol- % and about 60 vol-%, preferably about 65 vol-%, of an alcohol, preferably methanol, to elute a second MD-3 gradient fraction of the second MD-3 process.
- the sixth product of the present invention can be obtained by removing the aqueous solvent from the second MD-3 gradient fraction of the second MD-3 process.
- the present invention provides a sixth product that includes at least about 85% and preferably at least about 90% /r ⁇ m--resvcratrol (3,4',5- trihydroxy-/r ⁇ /7.y-stilbcne) which can be obtained by an extraction process.
- the extraction process includes removing aqueous solvent from the second MD-3 gradient -20-
- the extraction volumes are combined and the polar organic solvent is removed to obtain the sixth product having at least about 85% by weight tra -resveratrol.
- Yet another embodiment of the present invention is a crystallization process for making the substantially colorless product which comprises removing the aqueous solvent from the second MD-3 gradient volume of a first MD-3 elution volume of a second MD-3 process, dissolving the resulting solid at T>10°C in methanol, cooling to T ⁇ 0"C form crystals of the substantially colorless product and recovering the crystals of substantially colorless product by conventional means.
- the invention provides a partition crystallization process for making a sixth product that contains at least about 80% and preferably at least about 85% 3,4 , ,5-trihydroxy-tr ⁇ , -stilbene.
- Starting point for the partition crystallization process is a second MD-3 gradient fraction of a second MD-3 process.
- the second MD-3 gradient fraction is concentrated under vacuum to 0.35 to 0.40 times its original volume and a solid concentration of at least about 1,5 g/L.
- the concentrated gradient fraction is contacted with a polar organic solvent, preferably ethyl acetate.
- the volume of the polar organic solvent used is between bout 0.75 and about 0.85 time the volume of the concentrated second gradient fraction.
- the gradient fraction is contacted serially with two separate volumes of polar organic solvent and the volumes are combined.
- the polar organic solvent from single or multiple contactings, are evaporated to dryness to yield a sixth product having at least 80% 3,4',5-trihydroxy-tra/7. y -stiIbene. -21-
- Yet another embodiment of the present invention provides a seventh product that has at least about 50% and preferably at least about 55% more preferably at least about 60%, by weight of a stilbene fraction that includes at least about 50% by weight of 3,4',5-trihydroxy- -stilbene.
- the seventh product of the present invention can be prepared by a third MD-3 reverse phase liquid chromatography process.
- Starting material for the third MD-3 process is a second MD-2 gradient fraction of a second MD-2 process from which aqueous solvent is removed to form a loading concentrate having a solid content of at least 7 g/L.
- the loading concentrate thus formed is eluted through a conditioned MD-3 column.
- elution of the loading concentrate can be followed by elution of a washing elution volume including an aqueous solvent, preferably a mixture of alcohol and water having between about 5 vol-% and about 20 vol-% alcohol, preferably methanol.
- the washing elution volume when used, is followed by first and second MD-3 elution volumes of the third MD-3 process to produce, respectively, first and second effluents of the third MD-3 process.
- the first MD-3 elution volume of the third MD-3 process can include an aqueous solvent of a particular composition and can have two or more gradient volumes that when fractionate collected, result in two or more gradient fractions of a first effluent of the third MD-3 process.
- the first and second MD-3 elution volumes of the third MD-3 process include aqueous solvents which, in preferred embodiments, are mixtures of alcohol and water.
- the first MD-3 elution volume of the third MD-3 process preferably includes a mi.xture of alcohol and water comprising up to about 70% alcohol, preferably methanol.
- the first MD-3 elution volume of the third MD-3 process comprises first and second gradient volumes of a first MD-3 elution volume of a third MD-3 process that are mixtures of alcohol, preferably methanol, and water wherein the first MD-3 gradient volume of a first MD-3 elution volume of a third MD-3 process has between about 35 vol-% and about 45 ⁇ ol-%, preferably about 40 vol-%, alcohol and the second gradient volume of a first MD-3 elution volume of a third MD-3 process compiises between about 50 vol-% and about 60 vol-% preferably about 55 vol-%, alcohol
- the first elution volume of the third MD-3 process is a gradient elution volume and includes an aqueous solvent the composition of which is varied over the course elution of the first elution volume of a third MD-3 process according to a predetermined program
- the program may be linear, exponential, logarithmic, hyperbolic, step-wise, or a combination of the
- the second elution volume of the third MD-3 process is preferably a mixture of an alcohol, preferably methanol, and water including between about 80 vol-% and about 90 vol- %, preferably about 75 vol-% of alcohol
- the seventh product can be obtained by collecting a second MD-3 effluent of a third MD-3 process eluted by the second MD-3 elution volume of the third MD-3 process and removing the aqueous solvent therefrom
- the second MD-3 effluent of a third MD-3 process eluted by the second MD-3 elution volume of a third MD-3 process can be fractionate collected When the second MD-3 effluent of a third MD-3 process is fractionate collected, it mav be collected in any number of fractions In a preferred embodiment, the second effluent of the third MD-3 process is fractionate collected in two fractions
- the first fraction of the second effluent of the third MD-3 process preferably amounts to between about 0 5 and about 1 column volume
- the second fraction of the second effluent of the third MD-3 process preferably amounts to between about 0 5 and 2 0 column volumes and is a composition including the seventh product of the present invention
- "% alcohol” indicates the volume percent (vol-%) of alcohol in an alcohol - water mixture. Analysis of stilbene fractions was performed used HPLC on a Hewlett Packard Series 1 100 HPLC using an ODS H persil column.
- EXAMPLE 1 This example illustrates an MD-l process.
- the dried ground roots of Huzhang (Polygonum cuspidatitm) was extracted three times by percolation with 75% ethanol.
- the ethanol extract was concentrated at reduced pressure to a brown gummy semisolid (called Native Extract and abbreviated NE).
- the temperature during evaporation was kept between 35°C and 40 and the pressure was kept between 15-25 mm.
- About 1.4 kg of the NE (wet solid, Lot No. 7-1752) were dissolved in 4.9 L MeOH at 45°C and were stirred for 30 min. 44.1 L H;0 were added to the mixture (to yield 10% MeOH).
- the resulting mixture was loaded onto a water-conditioned, 4 in. x 35 in. MD-l column (containing Amberlite® resin, XAD-16HP).
- the column was eluted with a washing elution volume (2 CV of 10% MeOH) and then eluted with a first MD-l elution volume (7.7 CV of 75% MeOH) to obtain a first MD-l effluent.
- the first MD-l effluent (the best pool of fractions) from the MD-l column was concentrated from 126.4 L (75% MeOH ) to 35.5 L (19.5% MeOH) at 45°C for 1.5 hrs under vacuum in a still to form an MD-2 loading concentrate. Analysis indicated that the solids recovery is quantitative and the stilibene fraction of the solid component of the first MD-l effluent amounts to 24.2%.
- This example illustrates a second MD-2 process.
- the MD-2 loading concentrate from Example 1 was loaded onto a 10% MeOH conditioned, 4" x 49" MD-2 column having a polyamide resin as the stationary phase.
- the column was gradient eluted with a first gradient volume of a first MD-2 elution volume of a second MD-2 process (8 CV of 35% MeOH) and a second gradient volume of a first MD-2 elution volume of a second MD-2 process (6 CV of 75% MeOH).
- the first and second gradient fractions from 35% MeOH and 75% MeOH gradient volumes were fractionate collected.
- the solids component of first gradient fraction had a stilbene fraction of 44.4%, of which 60% was mono- ⁇ -D-glycosylated trihydroxy-t ⁇ -stilbene.
- the solids component of the second gradient fraction had a stilbene fraction of 35% of which 86% was trihysroxtstilbenes.
- This example illustrates removal of aqueous solvent from a composition.
- the alcohol - water mixture was removed from the second gradient fraction of Example 2 using a rotary evaporator (Biichi Rotavapor Model R-187 ) followed by drying in an tray vacuum oven. About 2L of the second gradient fraction (BZ 1-57-3 resveratrol pool, 75%
- This example illustrates making a sixth product of the present invention by a second MD-3 process. 20 L of a second MD-2 gradient fraction from a second MD-2 process (BZ1-
- MD-3 loading concentrate (6.28L, approx. 20% MeOH) that was eluted through a conditioned
- second MD-3 process (40% MeOI I) followed by 1.5 CV of a second MD-3 elution volume of a second MD-3 process (55% MeOH) that resulted in 1.5 CV of a second MD-3 effluent of a second MD-3 process.
- the best pool of /ra -resveratrol was fractionate collected as the first 1.1 CV of the second MD-3 effluent of a second MD-3 process, which contained a sixth product having a stilbene fraction that was 74.7% trihydroxy-iTw/.y-stilbene.
- 86.2% of the trihydroxy-tr ⁇ '-stilbenes present in the second gradient volume of the second MD-2 process were recovered.
- EXAMPLE 5 This example illustrates a partition crystallization process for purification of trihydroxy-tr ⁇ -stilbene.
- EXAMPLE 6 This example illustrates making a fifth product by a first MD-3 process.
- first MD-3 effluent of a first MD-3 process was fractionate collected.
- the best pool of /ro/w-piceid was fractionate collected between 1.68 CV and 2.20 CV (total of 0.52 CV) of the first MD-3 effluent of a first MD-3 process.
- the content of tr ⁇ /w-piceid in the stilbene fraction of the solid component of the best pool was 66% and 94% of the Irans-piccid loaded onto the MD-3 column was recovered.
- EXAMPLE 7 This E.xample illustrates evaporative crystallization to increase the purity of Cr ⁇ m'-piceid.
- Example illustrates making the third product by an MD-l process.
- the column Prior to use, the column was conditioned with 1 CV of 10% SDA at 7.2g stilbcne/L resin. The column was eluted with a washing elution volume ( 1 CV of 10% SDA) and then eluted with a first MD-l elution volume (3 CV of 90% SDA) to produce a first MD-l effluent. The first MD- l effluent was fractionate collected ( 1/2 CV per fraction) and the later 2'/ 2 CV (CK2-25-3-4) were pooled and collected as a composition containing the third product. The solids component of the combined later 2' ⁇ fractionate collected pool amounted to 424.2 g having a 25.5% stilbene fraction. EXAMPLE 9
- the following example illustrates a first MD-2 process for making a fourth product having 40% of a stilbene fraction.
- the loading was 8.9 g stilbene/L of stationary phase.
- the column was eluted with a washing elution volume (4 CV of 20% SDA) and was eluted with a first MD-2 elution volume of a first MD-2 process (4 CV of 75% SDA) to make a first MD-2 effluent.
- EXAMPLE 10 2 g NE (first product from Polygonum cuspidatitm, lot # 7-1752, 5.9% trans- piceid, 1 % c/s-piceid, 2.1% tr ⁇ -resveratrol, 2.9% .y-resveratrol, 1 1.9% total stilbene) were mixed with 5 ml of concentrated hydrochloric acid and 95 ml of Dl-water (5% HC 1). The solution was refluxed with agitation at 80"C under nitrogen for 60 minutes. /r ⁇ /?.y-Resveratrol (0.13 g) was isolated from the solution. Thus, 81.3% of all trihydroxystilbenes were converted to //W7. y -resveratrol (/r ⁇ -3,4 , ,5-trihydroxystilbene).
- EXAMPLE 1 1 The following example illustrates conversion of a ⁇ -D-glycosylated stilbene to the aglycone.
- 200 mg of 90% tr ⁇ /15-piceid (3,4'5-/rfl/ ⁇ .y-trihydroxystilbene -3- ⁇ -mono-D- glucoside, BZ 1-69-1) was mixed with 5 ml of concentrated hydrochloric acid and 95 ml water (5% HC1 v/v) and refluxed with agitation at 100°C for 90 minutes to yield 1 14g (57% yield) tr ⁇ -resveratrol (tra/ ⁇ _--3,4',5-trihydroxystilbene).
- DNA synthesis in HL-60 cells were 87%, 89%, and 79%inhibited, respectively, when cells are treated with 80 ⁇ g/ml concentrations of mixtures containing third products having 30% resveratrol, 40% stilbene, and 40% piceid, respectively.
- RNA synthesis levels were also inhibited by the aforementioned compounds at a concentration of 80 ⁇ g/ml by 93%, 91%, and 81 %, respectively.
- the amount of 3 [H 2 0] released as a byproduct of DMBA metabolism was inhibited by percentages of 69%, 70%, and 58% of the three previously mentioned compounds respectively, also at a concentration of 80 ⁇ g/ml. Test results are given in the Tables below.
- RPMI medium were incubated with various concentration of 30% resveratrol at 37"C in a 5%
- the third product used in this Example was obtained from the first gradient fraction of a second MD-2 process according to the method of Example 2.
- HL-60 5 x 10 5 cells
- RPMI medium 1 ml RPMI medium
- various concentration of 30% resveratrol at 37°C in a 5% C0 atmosphere incubator for 90 minutes.
- [ 3 H] thymidine incorporation into DNA was determined.
- the third product used in this Example was obtained from the first elution volume of a first MD-
- HL-60 (5 x 10 s cells) in 1 ml RPMI medium was incubated with various concentration of 30% resveratrol at 37"C in a 5% C0 2 atmosphere incubator for 90 minutes.
- This Example illustrates the anti tumor properties of a second product.
- DMBA dimethylbenz[a]anthracene
- EXAMPLE 14 The following Example illustrates the anti-tumor properties against various human tumor cell lines exhibited by various products of the present invention according to the results of in vitro 6-cell line clinical test.
- Cells were planted in 96 well flat bottom plates with low evaporation lids. Three cell lines per plate were seeded in 0.2 ml medium per well. Each cell line was planted at the optimum concentration for its particular growth rate: H-29 and A-549, 5000 c/ml, MCF-7, 15000 c/well, KB and similar cells, 2500 c/ml, P388 and similar cells, 15000 c/ml. Products were tested at various dilutions (at least ten) to determine the ED 50
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US217642 | 1988-07-12 | ||
US09/217,642 US6361815B1 (en) | 1998-12-21 | 1998-12-21 | Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use |
PCT/US1999/030425 WO2000037021A2 (en) | 1998-12-21 | 1999-12-21 | Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1140097A2 true EP1140097A2 (en) | 2001-10-10 |
EP1140097A4 EP1140097A4 (en) | 2002-05-08 |
EP1140097B1 EP1140097B1 (en) | 2003-11-12 |
Family
ID=22811901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99967471A Expired - Lifetime EP1140097B1 (en) | 1998-12-21 | 1999-12-21 | Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use |
Country Status (8)
Country | Link |
---|---|
US (1) | US6361815B1 (en) |
EP (1) | EP1140097B1 (en) |
AT (1) | ATE253917T1 (en) |
AU (1) | AU2374100A (en) |
CA (1) | CA2394949A1 (en) |
DE (1) | DE69912839T2 (en) |
ES (1) | ES2211219T3 (en) |
WO (1) | WO2000037021A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006082071A1 (en) * | 2005-02-04 | 2006-08-10 | Peter Heger | Method for producing a drug extract that contains hydroxystilbene |
US8268792B2 (en) | 2005-02-04 | 2012-09-18 | Peter Heger | Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1317033B1 (en) * | 2000-05-30 | 2003-05-26 | Istituto Di Medicina Speriment | METHOD OF EXTRACTION OF PHARMACEUTICAL ACTIVITY PRODUCTS FROM PLANTS SPERMATOPHYTES, PRODUCTS SO OBTAINED AND THEIR USE IN MEDICINE, IN |
KR100515066B1 (en) * | 2002-04-22 | 2005-09-14 | 한국생명공학연구원 | Novel compounds showing tyrosinase-inhibitive effect purified from Veratrum grandiflorum, and whitening compositions the same |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
CA2529510A1 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
BRPI0402260B1 (en) * | 2004-06-15 | 2015-02-18 | Botica Com Farmaceutica Ltda | Composition for toiletries, cosmetics and perfumes. |
AU2005262472B2 (en) * | 2004-06-16 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for modulating bax-mediated apoptosis |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US20070276172A1 (en) | 2006-03-28 | 2007-11-29 | Sinha Arun K | Single step microwave induced process for the preparation of substituted stilbenes and its analogs |
CA2745376A1 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
US20100215769A1 (en) * | 2009-02-24 | 2010-08-26 | Pero Ronald W | Natural occurring nutrient supplement compositions and methods of treatment using same by improving resistance to DNA damage, enhancing DNA repair and stimulating immune function wherein metabolic competition is avoided |
WO2010113005A2 (en) | 2009-03-27 | 2010-10-07 | Council Of Scientific & Industrial Research | One pot multicomponent synthesis of some novel hydroxy stilbene derivatives with alpha, beta-carbonyl conjugation under microwave irradiation |
JP2014527036A (en) | 2011-06-27 | 2014-10-09 | ザ ジャクソン ラボラトリー | Methods and compositions for the treatment of cancer and autoimmune diseases |
EP2875359A4 (en) | 2012-03-30 | 2015-08-19 | Charles R Drew University Of Medicine And Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS609455A (en) * | 1983-06-27 | 1985-01-18 | Osaka Chem Lab | Food containing stilbene compound extracted from specific polygonum plant as principal component |
FR2795965A1 (en) * | 1999-07-08 | 2001-01-12 | Actichem | METHOD FOR MANUFACTURING NATURAL EXTRACT OF RESERATROL CONCENTRATED VINE AND PRODUCTS |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1276225B1 (en) * | 1995-10-17 | 1997-10-27 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ALKANOYL L-CARNITINE IN ASSOCIATION WITH RESVERATROL OR ITS DERIVATIVES USEFUL FOR |
US6238673B1 (en) * | 1996-09-20 | 2001-05-29 | The Howard Foundation | Method of producing high flavonol content polyphenol compositions |
CN1055859C (en) * | 1997-04-16 | 2000-08-30 | 中国人民解放军空军总医院 | Application of stilbene compound and its derivative in preparation of endothelium element antagonist agent |
US6008260A (en) * | 1998-01-09 | 1999-12-28 | Pharmascience | Cancer chemopreventative composition and method |
US6022901A (en) * | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
-
1998
- 1998-12-21 US US09/217,642 patent/US6361815B1/en not_active Expired - Lifetime
-
1999
- 1999-12-21 AU AU23741/00A patent/AU2374100A/en not_active Abandoned
- 1999-12-21 WO PCT/US1999/030425 patent/WO2000037021A2/en active IP Right Grant
- 1999-12-21 CA CA002394949A patent/CA2394949A1/en not_active Abandoned
- 1999-12-21 ES ES99967471T patent/ES2211219T3/en not_active Expired - Lifetime
- 1999-12-21 EP EP99967471A patent/EP1140097B1/en not_active Expired - Lifetime
- 1999-12-21 AT AT99967471T patent/ATE253917T1/en not_active IP Right Cessation
- 1999-12-21 DE DE69912839T patent/DE69912839T2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS609455A (en) * | 1983-06-27 | 1985-01-18 | Osaka Chem Lab | Food containing stilbene compound extracted from specific polygonum plant as principal component |
FR2795965A1 (en) * | 1999-07-08 | 2001-01-12 | Actichem | METHOD FOR MANUFACTURING NATURAL EXTRACT OF RESERATROL CONCENTRATED VINE AND PRODUCTS |
Non-Patent Citations (4)
Title |
---|
JAYATILAKE G S ET AL: "KINASE INHIBITORS FROM POLYGONUM CUSPIDATUM" JOURNAL OF NATURAL PRODUCTS, XX, XX, vol. 56, no. 10, 1993, pages 1805-1810, XP000914921 ISSN: 0163-3864 * |
PATENT ABSTRACTS OF JAPAN vol. 009, no. 119 (C-282), 23 May 1985 (1985-05-23) & JP 60 009455 A (OOSAKA YAKUHIN KENKYUSHO:KK), 18 January 1985 (1985-01-18) * |
See also references of WO0037021A2 * |
TANAKA T ET AL: "A RESVERATROL DIMER FROM PARTHENOCISSUS TRICUSPIDATA" PHYTOCHEMISTRY, vol. 48, no. 7, 1998, pages 1241-1243, XP004289956 GB * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006082071A1 (en) * | 2005-02-04 | 2006-08-10 | Peter Heger | Method for producing a drug extract that contains hydroxystilbene |
US8268792B2 (en) | 2005-02-04 | 2012-09-18 | Peter Heger | Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases |
US9125857B2 (en) | 2005-02-04 | 2015-09-08 | Peter Heger | Method for producing a drug extract that contains hydroxystilbene |
Also Published As
Publication number | Publication date |
---|---|
US6361815B1 (en) | 2002-03-26 |
WO2000037021A2 (en) | 2000-06-29 |
DE69912839D1 (en) | 2003-12-18 |
WO2000037021A3 (en) | 2000-09-08 |
EP1140097B1 (en) | 2003-11-12 |
DE69912839T2 (en) | 2004-11-11 |
EP1140097A4 (en) | 2002-05-08 |
ATE253917T1 (en) | 2003-11-15 |
AU2374100A (en) | 2000-07-12 |
ES2211219T3 (en) | 2004-07-01 |
CA2394949A1 (en) | 2000-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1140097B1 (en) | Products comprising trihydroxystilbenes and derivatives thereof and methods for their manufacture and use | |
EP1734949B1 (en) | Purifications of ellagitannins | |
US6267995B1 (en) | Extract of Lepidium meyenii roots for pharmaceutical applications | |
Yesilada et al. | Isolation of anti-ulcerogenic sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis through bioassay-guided fractionation procedures in rats | |
KR102025322B1 (en) | Compounds having anti-inflammatory activity isolated from butterbur extract and isolation method thereof | |
US9174916B2 (en) | Compounds and uses thereof for treating inflammation and modulating immune responses | |
Huang et al. | Effect and mechanism of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) on hepatic fibrosis induced by carbon tetrachloride in rats | |
CN107298642B (en) | Extraction and purification method of 6-shogaol | |
KR101080648B1 (en) | A method for isolating and producing highly-concentrated Eupatilin and Jaceosidine from the extract of Artemisia species by using Centrifugal Partition Chromatography | |
CN116606269B (en) | Renilla diterpenoid compound and extract L01 and application thereof in pharmacy | |
JP3128823B2 (en) | Anticancer compound and method for producing the same | |
RU2411939C1 (en) | Method for synthesis of 2,3,6,7-tetrahydroxynaphthazarin | |
CN114057764B (en) | Linderane type dimeric sesquiterpene with anti-inflammatory activity and preparation method and application thereof | |
CN110721128B (en) | Cortex Mori extract and its preparation method | |
RU2401827C1 (en) | Rosmarinic acid sysnthesis method | |
KR20180100437A (en) | New molecules with anticancer activity | |
CN106822088B (en) | Application of diene iridoid compound in preparation of anti-cancer drugs | |
US10874705B2 (en) | Extracts and isolated compounds from cakile arabica for treatment of ulcer | |
KR100659771B1 (en) | Isolation of velutin and betulinic acid isolated from the organic extract of Korean mistletoe and its anti-tumor activity | |
Feng et al. | A pair of new enantiomeric hybrid phthalide–adenines with a rare 5-oxa-1-azaspiro [3, 4] octane moiety and two pairs of new enantiomeric hybrid paraethyl phenol–adenines from Ligusticum chuanxiong | |
CN110218208B (en) | Diels-Alder type compound and preparation method and application thereof | |
JPS61191687A (en) | Halichondrin b | |
Alexandrov | PRELIMINARY PHYTOCHEMICAL ANALYSIS OF IMPATIENS GLANDULIFERA ROYLE GRASS | |
CN116283874A (en) | Rhododendron dauricum hetero-terpenoid, extraction method and application | |
CN107459446A (en) | Needle juniper alkane type sesquiterpene compound and preparation method thereof and the purposes in pharmacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010720 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020326 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020902 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031112 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031112 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031112 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031112 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69912839 Country of ref document: DE Date of ref document: 20031218 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031221 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20031221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031231 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040212 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040212 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20040212 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI & CIE INGENIEURS-CONSEILS |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20031112 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2211219 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
26N | No opposition filed |
Effective date: 20040813 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20040412 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20081223 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20081230 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20090226 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20081223 Year of fee payment: 10 Ref country code: CH Payment date: 20090114 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20081230 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20091221 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091231 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091231 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091221 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20110310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110309 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091222 |